Aug. 5, 2022, 8:36 PM; Updated: Aug. 8, 2022, 8:34 PM
Cellex Inc. dropped its patent-infringement suit over the design of Siemens Healthineers AG’s Clinitest rapid Covid-19 antigen self-test just six days after filing the complaint, clearing the cloud it cast over their sizable sales, a filing in Delaware federal court says.
Cellex’s notice of voluntary dismissal, filed Aug. 4 in the US District Court for the District of Delaware, contained no details and didn’t mention a settlement. Cellex remains free to refile the suit.
Healthineers’ chief financial officer, Jochen Schmitz, told CNBC Aug. 3 that the company wasn’t expecting “any material effect” from Cellex’s suit. “It’s a design ...